Clinical trial
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung…
NCT00063154 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00063154 |
|---|---|
| Title | Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy |
| Official title | A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Pertuzumab |
| Enrollment | 51 |
| Start date | Jul 1, 2003 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Jun 25, 2003 |
| Last update posted | Jul 7, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: